Controversies in Drug Allergy: Drug Allergy Pathways

58Citations
Citations of this article
131Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Drug allergy pathways are standardized approaches for patients reporting prior drug allergies with the aim of quality improvement and promotion of antibiotic stewardship. At the International Drug Allergy Symposium during the 2018 American Academy of Allergy, Asthma, and Immunology/World Allergy Organization Joint Congress in Orlando, Florida, drug allergy pathways were discussed from international perspectives with a focus on beta-lactam allergy pathways and pragmatic approaches for acute care hospitals. In this expert consensus document, we review current pathways, and detail important considerations in devising, implementing, and evaluating beta-lactam allergy pathways for hospitalized patients. We describe the key patient and institutional factors that must be considered in risk stratification, the central feature of pathway design. We detail shared obstacles to widespread beta-lactam allergy pathway implementation and identify potential solutions to address these challenges.

Cite

CITATION STYLE

APA

Chiriac, A. M., Banerji, A., Gruchalla, R. S., Thong, B. Y. H., Wickner, P., Mertes, P. M., … Blumenthal, K. G. (2019, January 1). Controversies in Drug Allergy: Drug Allergy Pathways. Journal of Allergy and Clinical Immunology: In Practice. American Academy of Allergy, Asthma and Immunology. https://doi.org/10.1016/j.jaip.2018.07.037

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free